BioCentury | Dec 24, 2019
Company News

Dec. 23 Company Quick Takes: Theravance partners with Pfizer; plus Fortress-AZ, Progenics, Tracon-Alphamab Oncology-3D Medicines

...Corp. granted Tracon Pharmaceuticals Inc. (NASDAQ:TCON) development and commercialization rights in North America to envafolimab (KN035...
...Programmed cell death 1 ligand; PSMA (FOLH1; GCPII) - Prostate-specific membrane antigen Hongjiang Li, Staff Writer KN035...
BioCentury | Dec 11, 2019
Financial News

Local demand high for Alphamab Oncology’s Hong Kong IPO

...“Alphamab’s Cancer Cash” ). Alphamab Oncology has eight biologics in development. Its most advanced product, KN035...
...dMMR or MSI-H solid tumors. In January, Ascletis Pharma Inc. (HKEX:1672) gained China rights to KN035...
...T-lymphocyte associated protein 4; PD-L1 (B7-H1; CD274) Programmed cell death 1 ligand 1 Hongjiang Li, Staff Writer KN035...
BioCentury | May 28, 2019
Financial News

May 28 Financial Quick Takes: Alphamab Oncology raises $60M; plus $180.5M for Panacea healthcare fund and more

...and manufacturing site and to support its pipeline of biologics, including commercialization of lead product KN035...
BioCentury | Mar 1, 2019
Company News

Ex-Merck China R&D head joins Ascletis as CMO

...Ascletis gained China rights to an anti-PD-L1 antibody from Suzhou Alphamab Co. Ltd. (Suzhou, China), KN035...
BioCentury | Jan 18, 2019
Company News

Ascletis to develop Alphamab’s PD-L1 antibody for HBV in China

...subcutaneous anti-PD-L1 antibody KN035 for HBV and other viral diseases in greater China. Ascletis believes KN035...
...KN035 for Ascletis. Ascletis CFO Lindi Tan told BioCentury that if Alphamab gains approval of KN035...
...viral infection, Alphamab would be required to pay Ascletis upfront and milestone payments, plus royalties. KN035...
BioCentury | Jan 14, 2019
Company News

Ascletis to develop Alphamab’s PD-L1 antibody for HBV in China

...subcutaneous anti-PD-L1 antibody KN035 for HBV and other viral diseases in greater China. Ascletis believes KN035...
...KN035 for Ascletis. Ascletis CFO Lindi Tan told BioCentury that if Alphamab gains approval of KN035...
...viral infection, Alphamab would be required to pay Ascletis upfront and milestone payments, plus royalties. KN035...
BioCentury | Nov 21, 2018
Finance

Alphamab's cancer cash

...company’s bispecific antibody and antibody co-expression platforms to develop cancer therapies. Alphamab Oncology's lead product KN035...
BioCentury | Nov 16, 2018
Financial News

Alphamab Oncology raises more than $100M series A

...million in a series A round to accelerate development of its biologics including lead product KN035...
...Co. Ltd. (Suzhou, China) this year, taking with it four clinical and three preclinical biologics. KN035...
...antibody targeting CTLA-4 and PD-L1. The company has a fully owned subsidiary based in Suzhou. Hongjiang Li KN035...
BioCentury | Oct 26, 2018
Clinical News

Alphamab Oncology, 3DMed start Phase II of PD-L1 antibody in solid tumors

...Oncology (Suzhou, China) and 3D Medicines Corp. (Shanghai, China) began a Phase II trial of KN035...
...Co. Ltd. (Suzhou, China), which partnered with 3D Medicines in 2016 to develop and commercialize KN035...
...Fc fragment of human IgG1. Alphamab Oncology, Suzhou, China 3D Medicines Corp., Shanghai, China Product: KN035...
BioCentury | Oct 26, 2018
Clinical News

Alphamab Oncology, 3DMed start Phase III for PD-L1 antibody in cholangiocarcinoma

...Oncology (Suzhou, China) and 3D Medicines Corp. (Shanghai, China) began a Phase III trial of KN035...
...Co. Ltd. (Suzhou, China), which partnered with 3D Medicines in 2016 to develop and commercialize KN035...
...see "Alphamab, 3DMed Deal" ). Alphamab Oncology, Suzhou, China 3D Medicines Corp., Shanghai, China Product: KN035...
Items per page:
1 - 10 of 17